Status:
COMPLETED
Sponge Application of MMC Versus Suntenon Injection in Trabeculectomy
Lead Sponsor:
Al-Azhar University
Conditions:
Trabeculectomy
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Glaucoma is a leading cause of irreversible blindness worldwide, with intraocular pressure (IOP) reduction being the primary therapeutic goal. Trabeculectomy, augmented with mitomycin C (MMC), remains...
Eligibility Criteria
Inclusion
- 18 years or older,
- diagnosed with primary open-angle glaucoma (POAG) or secondary glaucoma,
- uncontrolled IOP (IOP \> 21 mmHg) despite maximally tolerated medical therapy,
- progressive visual field deterioration,
- or intolerance to anti-glaucoma medications.
Exclusion
- age under 18 years,
- absence of light perception,
- previous incisional glaucoma surgery,
- need for combined ocular procedures,
- intraoperative use of 5-fluorouracil (5-FU),
- or follow-up duration of less than one month
Key Trial Info
Start Date :
February 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2025
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06925412
Start Date
February 1 2024
End Date
March 1 2025
Last Update
April 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ebsar Eye Center
Cairo, Egypt, Egypt, 4450113